Research

Irish researchers to lead €3 million study on new cystic fibrosis medication

By hpnadmin July 30, 2020 Updated February 4, 2022 3 min read

Thursday, 30 July 2020 – Professor Paul McNally, Associate Professor of Paediatrics at RCSI, Respiratory Consultant in Children’s Health Ireland and lead researcher on the RECOVER study is pictured at the launch of a new €3m study, led by RCSI, to investigate the real-world effects of a new cystic fibrosis medication. Researchers at RCSI University of Medicine and Health Sciences are leading the international research project, called RECOVER, to look at how a new triple combination cystic fibrosis drug, Kaftrio, will affect people in their day to day lives. The project has been awarded €2.85 m from Cystic Fibrosis Foundation (US), €112 thousand from Cystic Fibrosis Trust (UK) and €100 thousand from Cystic Fibrosis Ireland. Photo credit: Julien Behal Photography NO FEE

Researchers at RCSI University of Medicine and Health Sciences are leading a new €3m study to investigate the real-world effects of the newest cystic fibrosis medications as they become available for people with CF.

The research will look at how a new triple combination cystic fibrosis drug, Kaftrio, will affect people in their day to day lives, rather than in controlled clinical trial conditions. Kaftrio (known as TriKafta in the US) is a successor to Orkambi.